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The mammalian neocortex is established from neural stem and progenitor cells that utilize specific transcriptional and environmental factors to
create functional neurons and astrocytes. Here, we examined the mechanism of Sox2 action during neocortical neurogenesis and gliogenesis. We
established a robust Sox2 expression in neural stem and progenitor cells within the ventricular zone, which persisted until the cells exited the cell
cycle. Overexpression of constitutively active Sox2 in neural progenitors resulted in upregulation of Notch1, recombination signal-sequence
binding protein-J (RBP-J) and hairy enhancer of split 5 (Hes5) transcripts and the Sox2 high mobility group (HMG) domain seemed sufficient to
confer these effects. While Sox2 overexpression permitted the differentiation of progenitors into astroglia, it inhibited neurogenesis, unless the
Notch pathway was blocked. Moreover, neuronal precursors engaged a serine protease(s) to eliminate the overexpressed Sox2 protein and relieve
the repression of neurogenesis. Glial precursors and differentiated astrocytes, on the other hand, maintained Sox2 expression until they reached a
quiescent state. Sox2 expression was re-activated by signals that triggered astrocytic proliferation (i.e., injury, mitogenic and gliogenic factors).
Taken together, Sox2 appears to act upstream of the Notch signaling pathway to maintain the cell proliferative potential and to ensure the
generation of sufficient cell numbers and phenotypes in the developing neocortex.
Crown Copyright © 2006 Published by Elsevier Inc. All rights reserved.Keywords: Astrocytes; Gliogenesis; Neural stem and progenitor cells; Neurogenesis; Precursors; Notch1; Proliferation; Sox2 degradationIntroduction
The mammalian central nervous system (CNS) arises from
progenitor cells that undergo a well-orchestrated program of cell
division, fate determination and differentiation (Jacobson,
1991; Qian et al., 1998, 2000; Rubenstein et al., 1998; Bertrand
et al., 2002). One of the earliest transcription factors expressed
in the developing CNS is Sox2 (Sex determining region of Y
chromosome (Sry)-related high mobility group box2), a member
of the extended Sox family (Gubbay et al., 1990; Laudet et al.,
1993; Koopman, 1999; Sasai, 2001). Sox proteins contain a
characteristic HMG domain that facilitates their interaction with
the minor groove of the DNA helix, causing DNA bending and
a transcriptionally permissive change in chromatin structure⁎ Corresponding authors. Fax: +1 613 990 7963.
E-mail addresses: mahmud.bani@nrc.ca (M. Bani-Yaghoub),
marianna.sikorska@nrc.ca (M. Sikorska).
0012-1606/$ - see front matter. Crown Copyright © 2006 Published by Elsevier In
doi:10.1016/j.ydbio.2006.03.007(Scaffidi and Bianchi, 2001; Weiss, 2001). Although they share
similar DNA-binding properties, the individual Sox proteins use
specific partners to regulate different sets of target genes
(Kamachi et al., 2000; Tanaka et al., 2004).
There is accumulating evidence that Sox2 controls the
expression of several developmentally important genes (Sox2,
Oct4, Nanog, nestin, δ-crystalline, fibroblast growth factor 4,
undifferentiated embryonic cell transcription factor 1 and F-box-
containing protein 15), hence, it plays a crucial role in embryonic
development (Pevny and Lovell-Badge, 1997; Wegner, 1999;
Kamachi et al., 2000; Avilion et al., 2003; Uchikawa et al., 2003,
2004; Catena et al., 2004; Miyagi et al., 2004; Wegner and Stolt,
2005). In particular, studies on the chick spinal cord show that
the inhibition of Sox2 activity in neural progenitors leads to their
exit from the cell cycle followed by early neuronal differenti-
ation (Bylund et al., 2003; Graham et al., 2003; Tanaka et al.,
2004). While several reports suggest a role for Sox2 in the
development of the CNS (Uwanogho et al., 1995; Zappone et al.,c. All rights reserved.
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the fundamental biological processes (i.e., proliferation, fate
determination or differentiation) depend on the Sox2 function.
Specifically, it is not known whether its role in neurogenesis
differs from that in gliogenesis or how the gene responds to the
factors that control the generation of neurons and glia.
Furthermore, although Sox2 inhibits neurogenesis (Bylund et
al., 2003; Graham et al., 2003; Tanaka et al., 2004), the
molecular mechanisms involved in this process are not known.
To address some of these questions, we examined the role of
Sox2 in the developing mouse neocortex. We established that
Sox2 expression was restricted to the proliferating cell
populations including neural stem and progenitor cells, glial
precursors and proliferating astrocytes. Neurons not only turned
the gene off, but also utilized a proteolytic serine-specific
pathway to eliminate the protein prior to terminal differentia-
tion. In contrast, terminally differentiated astrocytes, which
maintain a proliferative competence, were capable of switching
the gene on in order to transit from quiescence to proliferation.
Constitutive overexpression of Sox2 in neural progenitors
effectively inhibited neurogenesis and caused upregulation of
the molecular components of the Notch signaling pathway,
known for its role in the development of the CNS.
Materials and methods
Tissue isolation
Timed pregnant CD1 mice (Charles River, St. Constant, QC) were sacrificed
by CO2 inhalation at gestational (embryonic) days 9.5–18 (E9.5–E18), in
accordance with a protocol approved by the Canadian Council on Animal Care.
The uteruses were aseptically removed and transferred sequentially to two Petri
dishes containing calcium- and magnesium-free Hank's balanced salt solution
(HBSS, Invitrogen Corporation, Burlington, ON) to rinse away blood. Embryos
were dissected out of the amniotic sacs and examined for morphological
hallmarks to ensure the accuracy of the gestational timing. The heads and the
dorsal telencephalons were sequentially isolated under a dissection microscope
(Wild Heerbrugg, Germany) and transferred into new plates containing HBSS.
The dorsal telencephalons were freed of meninges and dissected further to
isolate the ventricular zone (VZ) or the neocortex, depending on the experiment
(i.e., cell culture, single cell clonal assay or biochemical, histochemical and
molecular analyses). Similar procedures were followed for the preparation of
adult and postnatal day 0–3 (PN0–PN3) neocortices.
Cell cultures
Tissues were mechanically dissociated in Dulbecco's Modified Eagle
Medium, high glucose, L-glutamine (DMEM; Invitrogen) and filtered through a
40-μm nylon cell strainer (Falcon, VWR, Mississauga, ON). The dissociated
cells were quickly assessed for viability by the trypan blue exclusion assay and
used as described below.
Neural stem cells and neurosphere assay
Neural stem cells were derived from the E13.5 cortical VZ and examined for
the self-renewal and multipotential properties (modified from Tropepe et al.,
1999; also see Seaberg and van der Kooy, 2003). In brief, cells were deposited
into the uncoated 96-well plates (Nunc) in DMEM (Invitrogen) + N2 supplement
(Invitrogen) + fibroblast growth factor 2 (FGF2, 20 ng/ml, Invitrogen) at a
density of 1 cell/well (plating efficiency: ∼40%). Single cells were repeatedly
monitored under a light microscope for the neurosphere formation, using the
same culture condition. After 7 days in vitro (DIV), a total of 70 ± 9.2 floating
primary neurospheres were generated from 10,000 cells (three independent
experiments). The primary neurospheres were divided into three groups: (a) 20neurospheres were used for immunocytochemical analysis of Sox2 and neuronal
and glial phenotypes; (b) another 20 neurospheres were transferred onto the PLL-
coated coverslips (Invitrogen) in DMEM + 5% fetal bovine serum (FBS;
Hyclone, Logan, UT) + N2 supplement and examined 1–10 days later for the
expression of Sox2 and neuronal and glial markers; (c) 25 of the remaining
primary neurospheres were dissociated separately into single cells to generate the
secondary neurospheres in DMEM + N2 supplement + FGF2 (i.e., one primary
neurosphere generated 32 ± 8.7 secondary neurospheres after 7 DIV).
Similar to the primary neurospheres, secondary neurospheres were divided
into three groups (25 each) and examined for: (a) Sox2, MAP2 and GFAP
expression; (b) multipotential properties by differentiation into neurons and
astrocytes; and (c) self-renewal capacity (i.e., one secondary neurosphere
generated 18 ± 5.2 tertiary neurospheres).
Neural progenitor, neuronal and astroglial cultures
Neural progenitors were obtained from the E13.5 VZ, plated onto PLL-
coated coverslips (9 × 105 living cells/ml) in DMEM + 5% FBS + N2
supplement and examined 4–8 h after plating. Neocortical neurons were
generated from neural progenitors (3–9 × 105 living cell/ml) by reducing the
serum concentration (i.e., 0.5% FBS) and adding 1 μM cytosine arabinoside
(Sigma-Aldrich Ltd., Oakville, ON) to the cultures between day 3 and 7 to limit
the generation of glial cells. Medium was replenished every 48 h during the
course of the experiment, and cells were examined at 3–7 DIV.
Astroglial cultures were generated from neural progenitors of the E13.5 VZ
(0.5–5 × 105 living cells/ml) in DMEM + 10% FBS (replenished every 48 h) and
were analyzed after 1–16 weeks. In some experiments, the 16-week-old
astrocytes were mechanically injured with a sterile p200 pipet tip and cultured
further for up to 7 days in the presence or absence of 40 ng/ml of FGF2,
100 ng/ml of ciliary neurotrophic factor (CNTF; Sigma), 15 ng/ml of leukemia
inhibitory factor (LIF; Invitrogen) or 1 mM dibutyryl cAMP (dbcAMP; Sigma)
in DMEM + 5% FBS (replenished every 48 h). The cultures were analyzed for
Sox2 expression and BrdU immunoreactivity, as described below.
Isolation of neuronal and glial precursors by immunopanning
Neuronal and glial precursors were isolated, as previously described (Mayer-
Proschel et al., 1997; Rao andMayer-Proschel, 1997). In brief, separate 100-mm
tissue culture plates were coated with 1 ml of either 5 μg/ml sterile A2B5
monoclonal antibody (Chemicon International, Inc., Temecula, CA) or 10 μg/ml
sterile E-NCAM monoclonal antibody (5B8 clone, Developmental studies
Hybridoma Bank, University of Iowa, IA) in PBS for 2–4 h. The plates were
washed three timeswith PBS just prior to the addition of cells. To isolate neuronal
precursors, the dissociated E13.5 dorsal telencephalic cells were added to the
A2B5-coated plate for 30 min (37°C, 5% CO2) and non-attached cells (i.e.,
remaining in suspension) were, subsequently, transferred into the E-NCAM-
coated plate. After 45 min (37°C, 5% CO2), the cells attached to the E-NCAM-
coated plate (i.e., A2B5-negative NCAM-positive) were scraped off, transferred
onto PLL-coated coverslips, placed in DMEM (Invitrogen) + 0.5% FBS
(Hyclone) + N2 supplement and were used for further analysis of the neuronal
cell lineage. To isolate glial precursors, the cells attached to the A2B5-coated
plate were scraped off and placed in the E-NCAM-coated plate for 45 min (37°C,
5% CO2). The non-attached (i.e., A2B5-positive NCAM-negative) cells were
collected, plated onto PLL-coated coverslips in DMEM + 10% FBS and were
used for analysis of the glial cell lineage. The cultures were examined for the
expression of A2B5, E-NCAM, Sox2, βIII tubulin, MAP2 and GFAP to
determine the efficiency of immunopanning and the fate of immunopanned cells.
Mouse embryonic stem cells
ES-D3 cells (ATCC,Manassas, VA) were seeded at a density of 5 × 105 living
cells/ml in a gelatin-coated T-25 flask in DMEM + 10% FBS (Gemini
BioProducts, Woodland, CA) + 1% non-essential amino acids (NEAA,
Invitrogen) + 2000 U/ml leukemia inhibitory factor (LIF, 105 Units/μg,
Invitrogen) + 0.001% β-mercaptoethanol (Sigma). To induce differentiation,
cells were removed from the substrate with trypsin–EDTA, gently dissociated
into a mixture of single cells and small clumps and transferred into four 100-mm
bacterial plates, each containing 10 ml of DMEM + 10% FBS + 1%NEAA. Cell
aggregates were grown for 4 days, during which the medium was refreshed once
(after 2 days). Following this period, cell aggregates were treated with
DMEM + 10% FBS + 1% NEAA + 1 μM RA for 4 days, during which the
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gently dissociated with trypsin–EDTA and plated into the laminin-coated tissue
culture dishes (that is, approximately 100 aggregates were plated into each 35-
mm plate, containing a coverslip). Cells were treated with DMEM + 10%
FBS + 1% NEAA and examined for neuronal and astroglial phenotypes at day
14, counting the first day of aggregation as day 1.
N2a neuroblasts
N2a neuroblastoma cells (ATCC) were plated at the density of 5 × 105 living
cells/ml in DMEM + 10% FBS and a day after plating were used for transient
transfections or retroviral infections, as described in Supplementary materials.
Human embryonic kidney (HEK) 293GPG cells
See Supplementary materials.
Inhibition of proteolysis
N2a cells were transfected with Sox2-EGFP or Sox2-cMyc constructs as
described in Supplementary materials. Twenty four hours after transfection, cells
were treated with individual protease inhibitors [i.e., 1 mM AEBSF
(Calbiochem, EMD Biosciences Inc., San Diego, CA), 10 μM E-64 (Sigma)
or 25 μM MG132 (Calbiochem)] for up to 30 h. The cell lysates were collected
and the proteins were resolved by 10% SDS-PAGE for Western blotting.
Inhibition of the Notch pathway
The retrovirally infected (Sox2-EGFP or EGFP alone) E13.5 VZ neural
progenitors (see Supplementary materials) were incubated in the absence or
presence of γ-secretase inhibitors X (final concentration: 10 μM; Calbiochem)
or II (final concentration: 150 μM; Calbiochem), starting 6 h after infection (Li
et al., 2000; Schroeter et al., 2003). Fresh inhibitor was added to the culture
every 24 h for 5 days in DMEM + 0.5% FBS + N2 supplement. Inhibitors were
solubilized in Dimethylsulfoxide (DMSO, Sigma) and diluted in medium. An
equal concentration of DMSO was also used in control cultures.
Tissue injury
In some experiments, CD1 mice (1 month old) were placed in a stereotaxic
frame and the skull was opened. The prefrontal association cortex was injured
using a Pasteur pipet connected to a vacuum pump. Animals were sacrificed by
CO2 inhalation at 0 and 5 days post-lesion and perfused with 4%
paraformaldehyde for 10 min. Brains were removed, fixed overnight, processed,
paraffin-embedded, sectioned and immunostained with Sox2 and GFAP
antibodies as described in Supplementary materials.
BrdU incorporation
Pregnant CD1 mice (13.5 day gestation) were injected intraperitoneally with
5-bromo-2-deoxyuridine (BrdU, Sigma), using 50 μg BrdU/g body weight.
After 2 h, animals were sacrificed and embryos were prepared for
immunohistochemical analysis, as described above. Following fixation, sections
were denatured in 4 N HCl (15 min), neutralized in 100 mM sodium tetraborate
pH 9.0 (15 min) and stained with monoclonal BrdU antibody.
Similarly, cells were incubated with 10 μM BrdU (final concentration) at
37°C, 5% CO2 (8–12 h), fixed in 4% paraformaldehyde (20 min), denatured,
neutralized and stained, as described above. The BrdU-immunoreactive cells
were visually scored against the Hoechst and Sox2-positive nuclei. Confluent
monolayers of quiescent astrocytes were scratched and incubated with 10 μM
BrdU (final concentration) and the factors (see Cell cultures) for 8–12 h (37°C,
5% CO2). Cultures were fixed at 15 min, 3 days and 7 days post-lesion, and their
Sox2 and BrdU immunoreactivity was determined, as described above.
Generation of SOX2 antibody
The antibody was raised against a full-length human SOX2, cloned into the
pBAD/His A vector (Invitrogen) and expressed as a (His)6-tagged SOX2 fusion
protein in E. coli strain LMG 194. The recombinant SOX2 was purified on aHis-Trap nickel column (Amersham Health, Oakville, ON). New Zealand
rabbits were injected with 500 μg of recombinant SOX2 and boosted three times
(250 μg each) within 4 weeks. The antibody titer was tested 10–14 days after
each boost and collected 14 days after the third injection. The specificity of
SOX2 antibody was validated in several tissues and cell lines.
Other antibodies
See Supplementary materials.
Statistical analysis
Data were derived from a total of three to five independent experiments
(each in triplicate). Cells were quantified in a uniform random fashion by
scoring the number of cells per field of view. Final values were presented as
means ± SEM, and their significance was determined by χ2 test, one-way
ANOVA and post hoc Dunnett's test, using GraphPad Instat (GraphPad
Software Inc., San Diego, CA).
Other methods
Gene delivery (including the detailed description of vectors), RT-PCR,
immunocytochemical, immunohistochemical and Western blotting methods
have been described in detail in the Supplementary materials.
Results
Characterization of Sox2 antibody
Analysis of Sox2 expression in the developing neocortex
requires a well-characterized antibody suitable for immuno-
chemistry and Western blotting. Therefore, in order to proceed
with this study, we generated a rabbit polyclonal antibody raised
against the full-length Sox2 protein and tested its immunore-
activity in tissues in which Sox2 is known to be present (i.e., the
blastocyst and the brain, Wegner, 1999). Our antibody showed
high specificity for Sox2 in immunocytochemical analysis,
revealing punctuate nuclear localization of Sox2 and no cross-
reactivity with the cytoplasmic components (Figs. 1A and B).
On Western blots, the antibody recognized the endogenous
Sox2 (34 kDa) as well as the overexpressed Sox2-EGFP fusion
protein (56 kDa), both as single protein bands (Figs. 1C–E).
Furthermore, the antibody did not cross react with other SoxB1
subfamily members, i.e., Sox1 and Sox3 (Fig. 1E). The
immunodetection capability of this antibody allowed us to
carefully examine Sox2 expression in the subsequent sets of
experiments.
Sox2 is spatially and temporally expressed in the neocortex
Western blot analysis showed abundant Sox2 expression in
the embryonic neocortex (Fig. 2A) during a time window in
which the pool of neural progenitors expands extensively to
satisfy the need for the generation of tens of thousands of
cortical neurons and astrocytes. These results were further
supported by immunohistochemical staining that showed Sox2
expression in neural stem and progenitor cells residing in the
ventricular zone (Figs. 2B and D). Sox2 expression was
dramatically downregulated after birth to a negligible level in
the adult mouse neocortex (Figs. 2A, F). The low level of Sox2
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by the SVZ neural stem cells, ependymal cells and a limited
number of dividing astrocytes (Ellis et al., 2004). Using a
2 h BrdU exposure of the E13.5 neocortex, we established that
the vast majority (i.e., 92 ± 6%, one-way ANOVA, P < 0.001) of
the BrdU-positive cells also showed Sox2 immunoreactivity
(Figs. 2D and E). However, cells leaving the ventricular zone
and acquiring neuronal identity did not stain with the Sox2
antibody (Figs. 2H and I). Instead, they were labeled with an
antibody specific for the transcription factor TBr-1, a marker of
newborn neurons (Fig. 2H). Neocortical neurons expressed TBr-
1 immediately after they exited the cell cycle and migrated out of
the ventricular zone at E11 (Fig. 2H). Later, at E13.5, TBr-1
staining displayed a gradient across the developing neocortex,
labeling the marginal zone and the cortical plate, but not the
ventricular zone (Fig. 2I). Furthermore, RT-PCR analysis con-
firmed that TBr-1 was expressed from the onset of neocortical
neurogenesis at E11 until its completion at E17 (Fig. 2J). Thus,
neocortical cells switched from Sox2-positive to Sox2-negative
TBr-1-positive status as they acquired neuronal identity.
Sox2 is downregulated as neocortical cells acquire neuronal
fate
To better understand the role of Sox2 in neural stem cells and
neuronal precursors, we examined Sox2 expression in these
subpopulations in the brain (Fig. 3A) and throughout their
differentiation in culture (Figs. 3B–M). The E13.5 ventricular
zone was dissociated into single cells (Figs. 3B and C) and
evaluated for self-renewal capability by neurosphere assays
(Figs. 3D and E). Sox2 was prominently expressed in both
single neural stem cells (Fig. 3B) and neurospheres (Fig. 3D).
The primary neurosphere cells maintained Sox2 expression
after dissociation and formation of the secondary neurospheres,
i.e., throughout the entire self-renewal process (data not shown).
In parallel experiments, we examined the generation of neurons
and astrocytes in more than 120 neurospheres and established
that neural stem cells turn off Sox2 as they differentiate into
neurons (Fig. 3F) but maintain its expression during gliogenesis
(Fig. 3H). The number of Sox2-negative MAP2-positive
neurons and Sox2-positive GFAP-positive astrocytes varied
depending on the size of neurospheres and the time at whichFig. 1. The in-house generated rabbit polyclonal antibody specifically detects
Sox2 protein. (A and B) Immunocytochemical examination of mouse embryonic
(A) and neural (B) stem cells reveals nuclear localization of Sox2. Arrowheads:
Sox2 in daughter cells at telophase. Scale bar: 10 μm. (C–E) Western blot
analyses with Sox2 antibody show a single 34-kDa band of endogenous Sox2 in
adult mouse brain (C, lane 1, whole brain; lane 2, cerebellum; lane 3,
hippocampus; lane 4, olfactory bulbs), mouse embryonic stem cells (D, lane 1)
and a single 56 kDa band of Sox2-EGFP fusion protein in transfected 293 cells
(D, lane 4; E, lane 4). Untransfected 293 cells (D, lane 2; E, lane 1) and EGFP-
transfected 293 cells (D, lane 3) were used as negative controls. The expression
level of β-actin (42 kDa) validates an equal protein loading. (E) Sox2 antibody
does not cross react with either Sox1 (E, lane 2) or Sox3 (E, lane 3), as evidenced
by the lack of immunoreactivity in samples expressing mouse recombinant Sox1
(Flag)-hrGFP (42 kDa) and Sox3(Flag)-hrGFP (43 kDa) proteins. Anti-Flag (E)
and anti-β-actin (E) blotting was used to verify transfection and equal protein
loading, respectively.
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by experiments on embryonic stem cells, in which the same
Sox2 behavior was observed during the generation of neurons
and astrocytes (Supplementary Fig. 1).
We applied a well-established immunopanning technique
with E-NCAM (PSA-NCAM) and A2B5 antibodies to isolate
the NCAM-positive A2B5-negative neuronal precursors
(Mayer-Proschel et al., 1997; Rao et al., 1998). Since NCAM
is a cell surface glycoprotein involved in the adhesion and
migration of neuronal precursors, it is routinely used to sort and
isolate these cells (Raff et al., 1983; Noll and Miller, 1993;
Mayer-Proschel et al., 1997; Rao and Mayer-Proschel, 1997;
Rao et al., 1998; Dietrich et al., 2002). These cells displayed
several important features. First, they were detected in a
transitory location, adjacent to the ventricular zone, where both
Sox2 and NCAM were present in the same cells (Fig. 3A).
Secondly, the level of Sox2 protein/cell was significantly lower
in neuronal precursors (44 ± 0.12%) than that of the cells
located in the VZ. Thirdly, the isolated NCAM-positive A2B5-
negative cells contained a small number of BrdU-positive (Fig.
3J) and Sox2-positive βIII tubulin-negative (13 ± 5%) cells after
24 h in culture. However, nearly all cells were Sox2-negative
after 3 DIV. Double immunostaining confirmed that over 90%
of cells were Sox2-negative βIII tubulin-positive after 3 DIV
(Fig. 3L) and Sox2-negative MAP2-positive after 7 DIV (Fig.
3M). Together, these results suggested that Sox2 downregula-
tion may be an essential step for neocortical cells to complete
neurogenesis. To validate this concept and better understand the
mechanism, we examined the fate of neural progenitors
following constitutive Sox2 overexpression.
Sox2 overexpression inhibits neurogenesis via the Notch
signaling pathway
Neural progenitors were efficiently (>90%) infected with the
retroviral particles carrying EGFP or Sox2-EGFP and carefullyFig. 2. Sox2 displays a spatiotemporal expression pattern in the developing
neocortex. (A) Western blot shows that Sox2 is highly expressed in the
embryonic neocortex, but it is significantly downregulated after birth. Expression
of β-actin (42 kDa) shows equal protein loading. (B) The immunohistochemical
analysis of E13.5 neocortex clearly demarcates Sox2 expression (green) in the
ventricular zone (VZ), where neural stem cells and progenitors are residing. (C)
Hoffmann modulation contrast image of E13.5 neocortex. Inset: the region
examined in panel B. (D–E) Sox2-positive neural progenitors (D, green) reside in
the proliferative E13.5 VZ, as demonstrated by BrdU staining (E, red).
Arrowheads: proliferating cells. (F) Most regions of the adult neocortex do not
express Sox2, with the exception of few cells in the ependymal layer. (G)
Hoffmann modulation contrast image of the adult neocortex. Inset: the region
examined in panel F. (H–I) Cells downregulate Sox2 (red), as they leave VZ and
adopt a TBr-1-positive neuronal identity (TBr-1, green). Note that the TBr-1-
positive neurons are Sox2-negative. This transition from Sox2-positive to TBr-1-
positive status coincides with an increase in neocortical neurogenesis from E11
(H) to E13.5 (I). (J) RT-PCR analysis confirms the absence of TBr-1 transcript
(175 bp fragment) at E9.5 and its subsequent presence during neurogenesis (E13
to E17). The β-actin transcript (297 bp fragment) was used as a control for RNA
input. E9.5–18: embryonic days 9.5–18; PN3: postnatal day 3; CP: cortical plate;
LV: lateral ventricle; MZ: marginal zone; Ncx: neocortex; VZ: ventricular zone.
Scale bar: B and F 400μm;C andG, 100μm;D andE, 50μm;H and I, 75μm.All
sections are sagittal.
Fig. 3. Neuronal precursors downregulate Sox2 as they exit the cell cycle. (A) The immunostaining of E13.5 neocortex (sagittal) demonstrates the presence of a Sox2-
positive NCAM-positive subpopulation (marked with arrowheads) at the outer boundary of the VZ (Sox2—green, NCAM—red). (B–I) A single Sox2-positive neural
stem cell (B) from VZ forms a Sox2-positive neurosphere (D), which, in turn, gives rise to neurons (F, MAP2—red, Sox2—green) and astrocytes (H, GFAP—red,
Sox2—green). While both cell types are derived from the same neural stem cell, only astrocytes maintain Sox2 expression (H). (C, E, G and I) Corresponding
Hoffmann modulation contrast images of panels B, D, F and H, respectively. (J) The NCAM-positive neuronal precursors (red) include a cell subpopulation that even
24 h after sorting still incorporates BrdU (green). (K) The phase contrast image of panel J. (L) The isolated NCAM-positive cells completely lose the Sox2 signal
within 3 days of sorting, as shown by double staining with Sox2 and neuronal βIII tubulin antibodies (Sox2—green, βIII tubulin—red). (M) Sox2 continues to be
absent in the MAP2-positive neurons at day 7 (Sox2—green, MAP2—red). MZ: marginal zone; VZ: ventricular zone. Scale bar: A, 20 μm; B–I, 10 μm; J–K, 12 μm;
L–M, 18 μm.
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control EGFP-tagged cells readily differentiated into both
neurons (Figs. 4A, B and G, 5 days after infection) and
astrocytes (Fig. 4G, 8 days after infection). By contrast,
neurogenesis (Figs. 4C and G), but not gliogenesis (Figs. 4D
and G), was severely inhibited in cultures expressing Sox2(FL)-
EGFP. The examination of Sox2-EGFP-positive cells after two
additional weeks in culture confirmed this outcome and ruled out
the possibility of delayed neurogenesis (data not shown). We
also used several truncated Sox2 constructs that carried the
HMG domain but lacked serine-rich region (i.e., amino acids
203–261), carboxyl tail (i.e., amino acids 262–317) or both (i.e.,
amino acids 203–317). The results showed that the N-terminal
fragment containing the HMG domain [Sox2(1–202)-EGFP]
was sufficient to confer the Sox2 inhibitory effect on neurogen-
esis (Figs. 4E and G, 5 DIV) without a significant effect on
gliogenesis (Figs. 4F, G, 8 DIV). The percentages of MAP2-
positive neurons and GFAP-positive astrocytes within the Sox2-
overexpressing populations (EGFP-positive cells) are presented
in Fig. 4G. The majority of the remaining cells (>70%, 5 DIV) in
these cultures were nestin-positive (data not shown).Fig. 4. Sox2 overexpression inhibits neurogenesis, but not gliogenesis. (A–B) The
mature neurons (B, MAP2—red). (C–D) Cultures infected with Sox2(FL)-EGFP do
readily give rise to the GFAP-positive astrocytes (D, Sox2—green, GFAP—red). (E–
do not differentiate into neurons (E, MAP2—red), but form astrocytes (F, GFAP—
ANOVA, P < 0.001) verifies the inhibition of neurogenesis by Sox2 and confirms th
confer this inhibition. Percentages of cell types within the infected populations are pUsing Sox2 overexpression, we also identified downstream
molecules that might underlie the molecular mechanism of
Sox2 function. Among the pathways involved in neocortical
development, Notch1 signaling plays a key role in inhibiting
neurogenesis (Beatus and Lendahl, 1998; Hitoshi et al., 2002).
Using the same retroviral system, we established that the levels
of Notch1, RBP-J and Hes5 transcripts were significantly
upregulated in response to Sox2 overexpression (Fig. 5A,
representative results from one of three experiments). Again,
the N-terminal fragment carrying the Sox2 HMG domain
[Sox2(1–202)] was sufficient for these effects.
In order to confirm that the upregulation of Notch pathway
by Sox2 is involved in the inhibition of neurogenesis, we both
repressed (Fig. 5) and activated (Supplementary Fig. 2) the
Notch signaling. Notch is activated through the binding of
Delta/Serrate/Jagged ligands, which triggers proteolytic events
requiring γ-secretase activity (Beatus and Lendahl, 1998;
Kimberly and Wolfe, 2003). The action of γ-secretase generates
a free Notch intracellular domain (Notch ICD) that translocates
into the nucleus and activates the transcription of target genes.
As shown in Figs. 5B–D, neurogenesis was partially restored inEGFP-tagged neural progenitors (A, EGFP—green) readily differentiate into
not form MAP2-positive neurons (C, Sox2—green, MAP2—red), while they
F) Similarly, cultures infected with N-terminal fragment of Sox2(1–202)-EGFP
red). Scale bar: 10 μm. (G) Statistical analysis of infected cultures (one-way
at the N-terminal fragment of Sox2 protein (amino acids 1–202) is sufficient to
resented as mean ± SEM.
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(Fig. 5C) or N-terminal Sox2(1–202) fragment (Fig. 5D)
upon treatment with the cell permeable γ-secretase inhibitor
X. Statistical analyses further confirmed that 19.7 ± 1.7% of
the Sox2(FL)-EGFP-positive cells were also positive for
MAP2 in the presence of γ-secretase inhibitor X, compared
with 0.4 ± 0.15% in the control cultures (i.e., infected with
Sox2(FL)-EGFP and incubated in the absence of the
inhibitor) at 5 DIV (one-way ANOVA, P < 0.001). Similarly,
16.8 ± 1.5% of the cells were Sox2(1–202)-EGFP-positive
MAP2-positive in the presence of γ-secretase inhibitor X at
5 DIV (one-way ANOVA, P < 0.001). Noticeably, the intensity
of nuclear Sox2 appeared to be lower in the MAP2-positive
cells in both cases. In addition, the overexpression of Notch1-
ICD or HES5 in neocortical progenitors also prevented their
differentiation into neurons (Supplementary Fig. 2), similar to
that of Sox2 (Fig. 5). Taken together, these results confirmed the
involvement of Sox2-activated Notch pathway in the inhibition
of neurogenesis.
Neuronal precursors and neuroblasts utilize serine protease(s)
to degrade the exogenous Sox2
Thus far, we showed that neural progenitors downregulated
Sox2 as they acquired neuronal fate, but the question still
remained how cells deal with constitutively active Sox2, which
clearly interfered with the terminal differentiation of neurons.
To address this issue, we extended the overexpression studies
to the NCAM-positive A2B5-negative neuronal precursors and
N2a neuroblasts, using similar transduction conditions.
Western blot analyses revealed that, within 48 h of infection/
transfection, both neuronal precursors and N2a neuroblasts
effectively degraded the exogenous Sox2 (Fig. 6A). This
phenomenon was unique to neuronal precursors (Fig. 6A, lane
3) and neuroblasts (Fig. 6A, lanes 5 and 7), as it was not
observed in the infected neural progenitors (Fig. 6A, lane 2).
Parallel experiments showed that other transcriptional factors/
transducers (i.e., MASH1 and Smad5) were not degraded and
further confirmed that the proteolytic process was specific to
Sox2 (Fig. 6B). Using specific groups of protease inhibitors,
we were able to establish that neuroblasts engage serine
protease activities to eliminate Sox2 protein (Fig. 6C). In
contrast, neither cysteine protease nor proteasome inhibitors
appeared to stop Sox2 degradation in neuroblasts.Fig. 5. Sox2 utilizes the Notch signaling pathway to inhibit neurogenesis. (A)
Specific components of Notch signaling pathway (i.e., Notch1, RBP-J and
Hes5) are upregulated in the cells transduced with Sox2 after 7 days in culture as
shown by RT-PCR analysis. Lane 1—molecular size markers (1 kb plus DNA
ladder), lane 2—E13.5 telencephalon (positive control; Hitoshi et al., 2002),
lane 3—cells infected with EGFP (negative control), lane 4—cells infected
with Sox2(FL)-EGFP and lane 5—cells infected with the N-terminal Sox2(1–
202)-EGFP. (B) In the absence of γ-secretase inhibitors, the neural progenitors
transduced with Sox2(FL)-EGFP do not form MAP2-positive neurons (Sox2—
green, MAP2—red). (C–D) Inactivation of the Notch pathway by γ-secretase
inhibitor X restores neurogenesis in the cells overexpressing either Sox2(FL)-
EGFP (C, Sox2—green, MAP2—red) or Sox2(1–202)-EGFP (D, Sox2—
green, MAP2—red). Scale bar: 10 μm.
Fig. 6. Neuronal precursors and neuroblasts utilize the serine-specific protease activity to degrade the exogenous Sox2. (A) Western blot analyses show that both
endogenous 34 kDa Sox2 (III) and exogenous 56 kDa Sox2-EGFP fusion protein (I) are intact in neural progenitors (lanes 1 and 2). However, the overexpressed Sox2-
EGFP protein undergoes extensive degradation in the NCAM-positive A2B5-negative neuronal precursors (lane 3, II). Similarly, N2a neuroblasts selectively degrade
overexpressed Sox2 (lanes 4 and 6—untransfected, lane 5—transfected with Sox2-EGFP, lane 7—transfected with Sox2-cMyc; I, II and III indicate overexpressed,
degraded and endogenous Sox2, respectively). (B) In contrast to Sox2, N2a neuroblasts do not degrade other CNS transcription factors and transducers such as
MASH1 (lane 1—untransfected, lane 2—transfected with MASH1-EGFP) or Smad5 (lane 3—untransfected, lane 4—transfected with Smad5-EGFP). (C) Sox2
degradation is inhibited by a selective inhibitor of serine protease in N2a cells (lane 1—untransfected; lanes 2, 3 and 8—transfected with Sox2-EGFP, no inhibitors;
lanes 4 and 5—transfected with Sox2-EGFP and treated with 1 mM AEBSF for 2 or 4 h, respectively), but not cysteine protease (lane 6—treated with 10 μME-64 for
4 h) or proteasome (lane 7—treated with 25 μMMG132 for 4 h) inhibitors. I, II and III indicate overexpressed, degraded and endogenous Sox2, respectively. β-actin
(42 kDa) validates an equal protein loading.
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off in quiescent astrocytes
TheA2B5 antigen is a commonly used cell surface marker that
identifies glial precursors (Mayer-Proschel et al., 1997; Rao,
2004; Rao and Mayer-Proschel, 1997; Rao et al., 1998). Using
this characteristic, we showed that neural progenitors maintained
Sox2 throughout gliogenesis (Fig. 7). The mitotically active
NCAM-negative A2B5-positive glial precursors (Figs. 7A–D)
readily differentiated into Sox2-positive GFAP-positive astro-
cytes (Fig. 7E) of flat (Fig. 7F) or stellate (Fig. 7G) shapes.
However, as the long-term cultures of astrocytes (i.e., 12–16
weeks in vitro) stopped proliferating, they also turned off Sox2
expression (Fig. 7H). The accompanying Western blot analyses
confirmed that, unlike neurons, astrocytes maintained Sox2
expression after they acquired glial fate, until they becamequiescent (Fig. 7I). Additional studies on cell cultures at other
developmental time points (i.e., E11 for neurons, and E17 or PN0
for astrocytes) consistently demonstrated the absence of Sox2 in
post-mitotic neurons and quiescent astrocytes (data not shown),
thus establishing a link between astroglial Sox2 expression and
cell cycle. This link was further confirmed in the quiescent astro-
cytic cultures that resumed proliferation after injury (Fig. 8).
Within 3 days post-lesion, Sox2-positive astrocytes appeared in
the proximity of the damaged area and increased in number after
7 days (Fig. 8D). The significance of injury-induced Sox2 reacti-
vation was more obvious with the application of CNTF (Fig. 8E),
FGF2 (Fig. 8F) or a combination of CNTF + FGF2 + dbcAMP
(Fig. 8G). Furthermore, these treatments clearly triggered cell
proliferation and resulted in the formation of stellate astrocytes,
which filled and repaired the damaged area (Figs. 8E–J).
Therefore, Sox2-positive cells clearly re-entered the cell cycle.
Fig. 7. Glial precursors maintain Sox2 expression as they differentiate into
astrocytes. (A–D) The immunopanned glial precursors express Sox2 (A and C,
green) and A2B5 (B, red) as they proliferate (D, BrdU—red). (E–G) Sox2
continues to be expressed in the GFAP-positive astrocytes (E, Sox2—green,
GFAP—red), regardless of their flat (F) or stellate (G) morphology. (H) In
contrast, the quiescent GFAP-positive astrocytes (red) do not express Sox2. Scale
bar: 10 μm. (I) Western blot analysis further confirms that neural progenitors
(lane 1) and astroglia (lanes 3–6), but not neurons (lane 2), express Sox2 and that
its expression level decreases with the age of astrocytes (compare lane 3 and 6).
Lanes 3–6 represent astrocytes after 1, 2, 4 or 8 weeks in culture, respectively.
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The re-expression of Sox2 was also observed in vivo upon a
mechanical injury of mouse brain tissue (Figs. 8K–N). Within
5 days of the injury, a significant number of Sox2-positive cells
were observed around the site of damage (Fig. 8M). The
majority of these cells were also GFAP-positive, which further
strengthens the link between Sox2 expression and gliogenesis.
These results also indicated that the expression of Sox2 gene
may be modulated by the brain microenvironment (i.e., the
mitogenic and gliogenic factors involved in the development of
the CNS). Among the trophic factors present in the brain, FGF2
exerts mitogenic effects on neural progenitors to increase the
cell number and expand the ventricular zone (Ford-Perriss et al.,
2001), whereas factors such as CNTF and LIF directly
contribute to the generation of astroglia by instructing a glial
fate (Panchision and McKay, 2002). We have examined the
effects of these factors on the neocortical cultures at the peak of
neurogenesis (i.e., E13.5) and the onset of gliogenesis (i.e.,
E18). A robust increase in the total number of Sox2-positive
cells was observed in the presence of FGF2 (Fig. 9A),
consistent with its mitogenic effects on neural progenitors.
Meanwhile, the number of Sox2-positive GFAP-positive
astrocytes remained nearly unchanged (Fig. 9A). Neither
CNTF nor LIF significantly increased the total number of
Sox2-positive cells at either time point (Fig. 9). Instead, these
factors significantly enhanced the number of Sox2-positive
GFAP-positive cells (i.e., the Sox2-positive astrocytic subpop-
ulation). The CNTF- and LIF-induced Sox2 expression in E18
cultures (Fig. 9B) was coincident with the onset of gliogenesis
in the neocortex. Finally, the number of total Sox2-positive cells
as well as Sox2-positive GFAP-positive cells was synergisti-
cally increased in the presence of both FGF2 and CNTF.
Discussion
Our study showed that Sox2 was expressed mainly in the
expanding cell population of the ventricular zone, in which the
appropriate pool of neural progenitors is generated to
subsequently establish a functional neocortex (Jacobson,
1991; Qian et al., 1998, 2000). The number of Sox2-positive
cells diminished postnatally as only ependymal cells and the
SVZ neural stem cells maintained Sox2 expression. A similar
reduction in the Sox2 level has also been documented during the
development of chicken spinal cord (Uwanogho et al., 1995;
Pevny and Rao, 2003). Using TBr-1 as a marker of early-born
cortical neurons (Bulfone et al., 1995; Donoghue and Rakic,
1999; Hevner et al., 2001, 2003; Chenn and Walsh, 2002), we
have shown a clear switch from a Sox2-positive to a TBr-1-
positive state during neocortical development. TBr-1 was first
detected at E11, when neurogenesis commences with the
generation of a single layer of neurons in the dorsal
telencephalon. TBr-1 expression was maintained until E17,
when the majority of the neocortical neurons have been formed.
Both this study and others (Bulfone et al., 1995; Donoghue and
Rakic, 1999; Chenn andWalsh, 2002) describe a TBr-1 gradient
Fig. 8. Quiescent astrocytes re-express Sox2 upon re-entry into the cell cycle. Neither BrdU (A) nor Sox2 (C) staining is present in the 16-week-old quiescent GFAP-
positive (red) astrocytes (C, 15 min post-lesion). (B) Phase contrast image of panel A. (D–G) Sox2 immunoreactivity is restored in the injured astrocytic cultures
(D, 7 days post-lesion), especially upon treatments with CNTF (E, 3 days post-injury), FGF2 (F, 3 days post-injury) or the combination of CNTF, FGF2 and
dbcAMP (G, 3 days post-injury). (H–I) The re-expression of Sox2 (H, 7 days post-injury + FGF2, Sox2—green) is accompanied by the cell cycle re-entry, as
evidenced by BrdU staining (I, red). (J) Phase contrast image of panels G, H and I. (K–N) The immunohistochemical analysis shows an abundant Sox2 re-expression
(M, green) near the injury site 5 days after the neocortex was lesioned. A similar section shows the level of Sox2 15 min after the injury (K). Panels L and N represent
the Hoffmann modulation contrast images of panels K and M, respectively (all sections are sagittal). Scale bar: A–J 10 μm; K–N 60 μm; inset 20 μm.
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was absent in the TBr-1-positive cells populating the newly
formed E11 marginal zone. The non-overlapping Sox2 and TBr-
1 expression patterns indicate that cells must turn off Sox2
before they adopt the TBr-1-positive identity in the neocortex.
Indeed, Sox2 was irreversibly turned off in terminally
differentiated post-mitotic neurons.
The upregulation of Notch pathway by Sox2 inhibits
neurogenesis
Several lines of evidence indicate that Sox2 is important for
the maintenance of neural potential in embryonic and neuralstem cells (Zappone et al., 2000; Graham et al., 2003; Ellis et al.,
2004; Zhao et al., 2004; Pevny and Placzek, 2005). Here, we
have demonstrated, for the first time, that Sox2 acts upstream of
the Notch signaling pathway. Indeed, Sox2 overexpression
caused the upregulation of Notch1, RBP-J and Hes5 genes and
blocked neurogenesis. Furthermore, γ-secretase inhibitors
(Kimberly and Wolfe, 2003) nullified the effects of Sox2 and
restored neurogenesis, whereas the overexpression of either
Notch1-ICD or HES5 mimicked the inhibitory effect of Sox2
overexpression.
Notch1 has been shown to preserve the pool of progenitors
and repress neurogenesis (but not gliogenesis) in the developing
CNS (Ishibashi et al., 1994; Nye et al., 1994; Kageyama and
Fig. 9. Sox2 expression is regulated by environmental factors. (A–B) The size of
Sox2-positive cell populations is regulated by environmental factors. FGF2 (a
mitogenic factor) significantly increases the total number of Sox2-positive cells
in the E13.5 (A) and E18 (B) neocortical cultures within a week. In contrast, the
CNTF and/or LIF gliogenic factors specifically increase the number of Sox2-
positive GFAP-positive astrocytes. The significance of data (mean ± SEM) was
determined by one-way ANOVA (*P < 0.05; **P < 0.05; ***P < 0.001).
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et al., 2002; Grandbarbe et al., 2003; Tokunaga et al., 2004).
The activation of Notch signaling occurs in response to ligand
binding (i.e., a member of Delta/Serrate/Jagged family), and the
proteolytic activity of γ-secretase is required to generate the free
Notch1 ICD, which in turn, translocates into the nucleus and
activates the transcription of target genes such as cyclin D1 and
cyclin-dependent kinases (Castella et al., 2000; Ronchini and
Capobianco, 2001; Hansson et al., 2004). Notch1 has also been
shown to upregulate Hes genes via interaction with RBP-J
(Artavanis-Tsakonas et al., 1995; Beatus and Lendahl, 1998;
Beatus et al., 2001).
The Sox2 HMG domain, a signature motif for DNA binding
and potential interactions with other partners (Yuan et al., 1995;
Johnson et al., 1998; Nowling et al., 2000), was sufficient for
the upregulation of Notch pathway and inhibition of neurogen-
esis. Based on the current knowledge, there is no obvious
explanation for the effects of the truncated Sox2. However, it is
possible that, in addition to the cell type- and partner-specificfunctional features of the C-terminus (Kamachi et al., 1999,
2000), the truncated protein contains yet unidentified domain(s)
that are clearly sufficient to confer its functionality.
Thus far, very little is known about Sox2 involvement in
transcriptional regulation of the Notch pathway. However, the
fact that Sox1 (i.e., a member of SoxB1 subfamily) regulates the
Hes1 promoter in P19 cells (Kan et al., 2004) raises the
possibility that Sox2 may regulate the Hes5 promoter through a
similar mechanism. Furthermore, recently published genome
scale (i.e., chromatin immunoprecipitation coupled with micro-
array) analysis of OCT4, NANOG and SOX2 target genes in
human stem cells has identified NOTCH1 as a direct target of
SOX2 and revealed that these transcription factors frequently
co-occupy target gene promoters to form a unique transcrip-
tional hierarchy that is essential in early development (Boyer et
al., 2005).
The number of identified Sox2 target genes is still relatively
small; hence, Sox2-binding element(s) are not well character-
ized. However, two recent studies report that a short DNA
sequence (CTTTGTT in the Fgf4 enhancer and TATTGTT in
the c-myc scaffold or matrix attachment region, S/MAR) makes
physical contact with Sox2 protein (Remenyi et al., 2004; Lei et
al., 2005). Significantly, the binding of SOX2 to the latter
sequence correlates with the expression of c-myc transcripts in
proliferating human NT2 neuronal precursors, consistent with
SOX2 being required for the correct level of c-myc transcription
in cycling cells. We applied the SMARTest module of the
Genomatix Suite integrated bioinformatics software package
(Genomatix Software GmbH, München, Germany; Liebich et
al., 2002; Frisch et al., 2002) to examine the genomic sequences
from 10 kbp upstream to 10 kbp downstream of Notch1 acc. #
NM_008714), Hes5 (acc. # NM_010419) and RBP-J (acc. #
NM_009035) genes for the presence of S/MARs. Using the
sequences from UCSC mouse genome version mm6 via the
UCSC Genome Browser (Kent et al., 2002), we showed that the
mouse RBP-J gene contained seven predicted S/MAR sites.
Five of the seven putative RBP-J S/MARs sites contained Sox2-
like binding regions, with one (located between nucleotides
60,686 and 61,015) enclosing a putative base unpairing region
(BUR) core motif. These features of RBP-J gene are very
similar to those of c-myc, suggesting a mechanism by which
Sox2 may enhance the expression of RBP-J by binding to
S/MAR and possibly within a BUR.
Inactivation of Sox2 by proteolysis
We have also examined the turnover of Sox2 protein during
terminal differentiation of neuronal (NCAM-positive) and glial
(A2B5-positive) precursors. Both populations initially
contained Sox2-positive cells. However, the level of Sox2
protein in the cells that followed the neuronal lineage was
significantly lower than that of the cells residing in the VZ or the
A2B5-positive glial precursors. Furthermore, overexpression of
Sox2 in NCAM-positive neuronal precursors resulted in its
degradation. Thus, the cells already committed to the neuronal
lineage have in place a degradation mechanism to eliminate
Sox2. This mechanism appeared to be specific to Sox2 protein as
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Smad5) were not affected by proteolysis. These observations
revealed, for the first time, the existence of a post-translational
mechanism controlling the precise level of Sox2 during neuro-
genesis. Indeed, a serine-specific proteolytic pathway, sensitive
to an irreversible inhibitor (i.e., AEBSF), appeared to be respon-
sible for Sox2 degradation. This activity was different from that
affecting another Sox family member, Sox9, which is inactivated
by the ubiquitin–proteasome system during chondrogenesis
(Akiyama et al., 2005). Thus, it is possible that cells engage cell-
type-specific pathways to control the level of Sox proteins
according to their functional and phenotypic requirements.
Sox2 in gliogenesis
Sox2 did not interfere with gliogenesis as glial precursors
maintained Sox2 expression throughout differentiation and as
long as they continued to divide. Astrocytes turned off the gene
as they became quiescent. However, they re-expressed Sox2 and
resumed proliferation upon stimulation. Thus, Sox2 expression
was mainly restricted to mitotically active neocortical cell
populations, including neural progenitors and GFAP-positive
astrocytes.
Numerous studies (see Silver and Miller, 2004 for a review)
show that terminally differentiated astrocytes can resume
proliferation upon activation (i.e., after brain injury). Here, we
showed that injured astrocytes re-expressed Sox2 both in vitro
and in vivo as they re-entered the cell cycle. Furthermore, the
exposure of injured astrocytes to either FGF2 or CNTF, whose
elevated expression has been demonstrated following injury
(Banner et al., 1997; Silver and Miller, 2004), significantly
increased the number of Sox2-positive proliferating astrocytes.
This phenomenon suggested that both FGF2- and CNTF-
mediated pathways (Lillien and Raff, 1990; Bonni et al., 1997;
Cavanagh et al., 1997; Vaccarino et al., 1999; Ford-Perriss et al.,
2001; Monville et al., 2001; Dallner et al., 2002) may be
involved in the regulation of Sox2 expression. However, further
studies are required to establish which of the regulatory
elements in Sox2 enhancers (Zappone et al., 2000; Uchikawa
et al., 2003, 2004; Catena et al., 2004; Miyagi et al., 2004;
Rodda et al., 2005) are influenced by these pathways.
In summary, the present study established that Sox2 functions
as a key regulator of proliferative potential of neocortical cells (i.e.,
neural stem and progenitor cells, glial precursors and astrocytes).
Its function interfered with neurogenesis, but not gliogenesis.
Committed neuronal precursors utilized a serine protease activity
to eliminate Sox2 protein. Sox2 acted upstream of the Notch
signaling pathway, and the Sox2 HMG domain was sufficient to
upregulate Notch and inhibit neurogenesis. Thus, neural progeni-
tors could differentiate into neurons when Sox2 was turned off
and/or degraded and the Notch1 signaling was repressed.
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